Implementing stereotactic accelerated partial breast irradiation using magnetic resonance guided radiation therapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
11 2021
Historique:
received: 06 01 2021
revised: 06 09 2021
accepted: 20 09 2021
pubmed: 9 10 2021
medline: 31 12 2021
entrez: 8 10 2021
Statut: ppublish

Résumé

Accelerated partial breast irradiation (APBI) seeks to reduce irradiated volumes and radiation exposure for patients while maintaining acceptable clinical outcomes. Magnetic resonance image-guided radiotherapy (MRgRT) provides excellent soft-tissue contrast for treatment localization, which can reduce setup uncertainty, thus reducing margins in the external beam setting. Additionally, stereotactic body radiotherapy (SBRT)-style regimens with high gradients can also be executed. This MR-guided stereotactic APBI (MRgS-APBI) approach can be utilized for a lower number of fractions and spare a greater volume of healthy tissues compared to conventional 3D external beam APBI. Our MRgS-APBI program was developed for two prospective non-randomized phase I/II clinical trials (20Gyx1 and 8.5Gyx3). Both breast SBRT treatment planning and MRgRT delivery techniques were described in this study. Simulation included both CT and MRI with specialized immobilization to accommodate MR-guided setup and cine-MRI treatment gating. Dosimetry data from 48 single-fraction and 19 three-fraction patients were collected and evaluated. This included planning objectives and SBRT-specific indices. During treatment, setup errors were calculated to evaluate setup reproducibility and duty cycle was calculated using cine-MRI data during gated delivery. In both the single- and three- fraction trials combined, 88.5% of the possible dosimetric objectives across all patients were met during planning. The majority of the planning objectives were easily achievable indicating the potential for stricter objectives for subsequent S-APBI treatments. The average magnitude of setup uncertainties was 1.0 cm ± 0.6 cm across all treatments. In the three-fraction trial, the average beam-on duty-cycle for the MRI-gated delivery was 83.0 ± 13.0%. There were no technical MRgS-APBI related issues that resulted in discontinuation of treatment across all patients. SBRT-style dosimetry and delivery for APBI is feasible using MR-guidance. The program development and dosimetric outcomes reported here can serve as a guide for other institutions considering the clinical implementation of MR-guided stereotactic APBI.

Identifiants

pubmed: 34624406
pii: S0167-8140(21)06746-3
doi: 10.1016/j.radonc.2021.09.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

275-281

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest Statement Drs. Green, Henke, and Mr. Price report personal fees from ViewRay, Inc., outside the submitted work. Mr. Price also reports personal fees from SunNuclear Corporation outside the submitted work. Dr. Zoberi reports speaker fees from ViewRay, Inc., outside the submitted work. Dr. Henke also reports grants and other from Varian Medical Systems, outside the submitted work.

Auteurs

Alex T Price (AT)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

William R Kennedy (WR)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Lauren E Henke (LE)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Sean R Brown (SR)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Olga L Green (OL)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Maria A Thomas (MA)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

John Ginn (J)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States.

Imran Zoberi (I)

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, United States. Electronic address: izoberi@wustl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH